» Articles » PMID: 31319185

Clinical Factors Associated With Gastric Cancer in Individuals With Lynch Syndrome

Overview
Specialty Gastroenterology
Date 2019 Jul 19
PMID 31319185
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Lynch syndrome is the most common inherited cause of gastrointestinal cancer and increases risk for a variety of malignancies, including gastric cancer. We aimed to identify clinical factors associated with gastric cancer in carriers of germline variants causing Lynch syndrome.

Methods: We collected data from 52,758 consecutive individuals tested for genetic variants associated with Lynch syndrome from June 2006 through July 2013 at a commercial laboratory. We obtained clinical and demographic data, as well as information on personal and family histories of cancer (first- and second-degree relatives) from forms completed by ordering providers. We performed multivariate logistic regression to identify clinical factors associated with gastric cancer in carriers of mutations that cause Lynch syndrome (pathogenic mutations).

Results: After we excluded individuals with missing clinical data (n = 1664) or with multiple pathogenic mutations (n = 8), we analyzed data from 51,086 individuals. Of these, 3828 persons carried pathogenic mutations (1346 with mutations in MLH1, 1639 with mutations in MSH2, 670 with mutations in MSH6, 145 with mutations in PMS2, and 28 with mutations in EPCAM). Of the 3828 carriers of pathogenic mutations, 41 (1.1%) had a previous gastric cancer and 350 (9.1%) had 1 or more first- or second-degree relatives with gastric cancer. In multivariate analysis, male sex (odds ratio [OR], 2.82; 95% CI, 1.48-5.38), older age (OR, 2.07 per 10 years; 95% CI, 1.64-2.61), mutations in MLH1 (OR, 6.53; 95% CI, 1.50-28.42) or MSH2 (OR, 5.23 compared to mutations in MSH6, PMS2, or EPCAM; 95% CI, 1.21-22.71), and number of first-degree relatives with gastric cancer (OR, 2.52; 95% CI, 1.42-4.45), but not second-degree relatives (OR, 1.12; 95% CI, 0.40-3.18) were independently associated with gastric cancer among carriers of pathogenic mutations.

Conclusions: In an analysis of data from almost 4000 carriers of Lynch syndrome-associated mutations, we found history of gastric cancer to be independently associated with male sex, older age, mutations in MLH1 or MSH2, and number of first-degree relatives with gastric cancer. These findings suggest that personalized, risk-stratified approaches to gastric cancer surveillance may be appropriate for individuals with Lynch syndrome-associated mutations.

Citing Articles

High risk of multiple gastric cancers in Japanese individuals with Lynch syndrome.

Kanaya N, van Schaik T, Aoki H, Sato Y, Taniguchi F, Shigeyasu K Ann Gastroenterol Surg. 2024; 8(6):1008-1016.

PMID: 39502732 PMC: 11533028. DOI: 10.1002/ags3.12809.


Risk of Gastric and Small Intestinal Cancer in Patients With Lynch Syndrome: Data From a Large, Community-Based US Population.

Lin C, Carwana H, Jiang S, Li D Clin Transl Gastroenterol. 2024; 15(9):e1.

PMID: 39320958 PMC: 11421716. DOI: 10.14309/ctg.0000000000000739.


Dual primary gastric and colorectal cancer: The known hereditary causes and underlying mechanisms.

Azer S World J Gastrointest Oncol. 2024; 16(6):2264-2270.

PMID: 38994141 PMC: 11236243. DOI: 10.4251/wjgo.v16.i6.2264.


Quadruple primary tumors in a lynch syndrome patient surviving more than 26 years with genetic analysis: a case report and literature review.

Zhu B, Liu M, Mu T, Li W, Ren J, Li X Front Oncol. 2024; 14:1382154.

PMID: 38894864 PMC: 11184617. DOI: 10.3389/fonc.2024.1382154.


Bleeding Mass in Remnant Stomach, Unveiling Lynch Syndrome 18 Years After Bariatric Roux-En-Y Gastric Bypass Surgery.

Qazi A, Mathur K, Rosen R, Stroud A, Webber J, Mutchnick M ACG Case Rep J. 2024; 11(4):e01323.

PMID: 38586822 PMC: 10997321. DOI: 10.14309/crj.0000000000001323.


References
1.
Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F . Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 2014; 23(5):700-13. PMC: 4019373. DOI: 10.1158/1055-9965.EPI-13-1057. View

2.
Stoffel E, Mangu P, Gruber S, Hamilton S, Kalady M, Lau M . Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2014; 33(2):209-17. PMC: 5321096. DOI: 10.1200/JCO.2014.58.1322. View

3.
Ten Broeke S, van der Klift H, Tops C, Aretz S, Bernstein I, Buchanan D . Cancer Risks for PMS2-Associated Lynch Syndrome. J Clin Oncol. 2018; 36(29):2961-2968. PMC: 6349460. DOI: 10.1200/JCO.2018.78.4777. View

4.
Soer E, Leicher L, Langers A, van de Meeberg P, van der Wouden E, Koornstra J . Equivalent Helicobacter pylori infection rates in Lynch syndrome mutation carriers with and without a first-degree relative with gastric cancer. Int J Colorectal Dis. 2016; 31(3):693-7. DOI: 10.1007/s00384-016-2524-7. View

5.
LaDuca H, McFarland R, Gutierrez S, Yussuf A, Ho N, Pepper J . Quality of Clinician-Reported Cancer History When Ordering Genetic Testing. JCO Clin Cancer Inform. 2019; 2:1-11. DOI: 10.1200/CCI.18.00014. View